SciClone Pharmaceuticals to Report Financial Results for the

SciClone Pharmaceuticals to Report Financial Results for the Third
Quarter 2012 and 2012 Outlook on November 9th 
FOSTER CITY, CA -- (Marketwire) -- 11/08/12 --  SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to
report third quarter 2012 financial results and 2012 outlook on
Friday, November 9, 2012. SciClone will host a conference call and
webcast to provide a business and product update at 8:30 am ET that
day. The call will be hosted by Friedhelm Blobel, Ph.D., President
and CEO, and Gary Titus, Senior Vice President and CFO. 
LIVE CALL: 
 877-261-8992 (U.S./Canada)
 847-619-6548
(International)
 Passcode: 33695874 
REPLAY: 
 888-843-7419 (U.S./Canada)
 630-652-3042 (International) 
Passcode: 33695874 
 (Replay available from Friday, November 9, 2012,
at 11:00 am ET until 11:59 pm ET on Wednesday, November 14, 2012) 
The conference call will contain forward-looking statements.
Interested parties who wish to listen to the webcast should visit the
Investor Relations section of SciClone's website at www.sciclone.com.
The information provided on the teleconference is accurate only at
the time of the conference call, and SciClone will take no
responsibility for providing updated information except as required
by law.  
About SciClone  
SciClone Pharmaceuticals is a revenue-generating, profitable,
specialty pharmaceutical company with a substantial commercial
business in China and a product portfolio of therapies for oncology,
infectious diseases and cardiovascular, urological, respiratory, and
central nervous system disorders. SciClone's ZADAXIN(R) (thymalfasin)
is approved in over 30 countries and may be used for the treatment of
hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and
certain cancers according to the local regulatory approvals. Besides
ZADAXIN, SciClone markets about 15 mostly partnered products in
China, including Depakine(R), the most widely prescribed
broad-spectrum anti-convulsant in China; Tritace(R), an ACE inhibitor
for the treatment of hypertension; Stilnox(R), a fast-acting hypnotic
for the short-term treatment of insomnia (marketed as Ambien(R) in
the US); and Aggrastat(R), a recently-launched interventional
cardiology product. SciClone is also pursuing the registration of
sever
al other therapeutic products in China. SciClone is
headquartered in Foster City, California. For additional information,
please visit www.sciclone.com.  
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts: 
Gary Titus 
Chief Financial Officer 
650.358.3456 
gtitus@sciclone.com  
Jane Green 
Investors/Media
650.358.1447
jgreen@sciclone.com 
 
 
Press spacebar to pause and continue. Press esc to stop.